Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Common Equity (2016 - 2025)

AC Immune has reported Common Equity over the past 11 years, most recently at $56.2 million for Q4 2025.

  • Quarterly Common Equity fell 56.18% to $56.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $56.2 million through Dec 2025, down 56.18% year-over-year, with the annual reading at $56.2 million for FY2025, 56.18% down from the prior year.
  • Common Equity was $56.2 million for Q4 2025 at AC Immune, down from $90.3 million in the prior quarter.
  • Over five years, Common Equity peaked at $251.6 million in Q4 2021 and troughed at $56.2 million in Q4 2025.
  • The 5-year median for Common Equity is $155.0 million (2023), against an average of $152.3 million.
  • Year-over-year, Common Equity rose 5.55% in 2021 and then crashed 56.18% in 2025.
  • A 5-year view of Common Equity shows it stood at $251.6 million in 2021, then plummeted by 30.27% to $175.4 million in 2022, then increased by 3.24% to $181.1 million in 2023, then decreased by 29.23% to $128.2 million in 2024, then tumbled by 56.18% to $56.2 million in 2025.
  • Per Business Quant, the three most recent readings for ACIU's Common Equity are $56.2 million (Q4 2025), $90.3 million (Q2 2025), and $128.2 million (Q4 2024).